Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Sepracor-Looks very promising -- Ignore unavailable to you. Want to Upgrade?

To: Lighthouse who wrote (4227)	2/27/2000 9:09:00 PM
From: Ed Ajootian	Read Replies (1) \| Respond to of 10280

Thanks Lighthouse for the report. Last week's action seems to be more than just the result of a hot biotech market and the stock being about to split. Interesting to speculate about what news may be coming out. If I recall correctly they are due to have finished another study on Xopenex. Also, wondering whatever happened to that company they founded awhile ago, Versicor. Thought that one had a lot of promise, and with this hot biotech market it would seem that they oughtta seize this opportunity to take that public like they did with two other subs. several years ago. If they don't do it now, when will they? Can't wait for some big news to come out, and then we'll have David Southwell get interviewed on the CNBC squawk box again, and maybe this time he'll say they'll earn, say $20 a share in '03. I'll sell into that hype, at an average price of $150 (post-split). Then I'll buy back in a month later at $100.

To: Lighthouse who wrote (4227)	2/28/2000 1:42:00 AM
From: Dave K	Read Replies (1) \| Respond to of 10280

Anyone on SEPR thread know if this collaboration between SEPR & ANDRX on Allegra is intact i.e. royalties flow to ADRX. I'm doing DD on ADRX but can't find mention of this pact in SEPR filings. ADRX 10K....1998 In April 1996, the Company entered into a collaboration agreement for the development of a brand name controlled-release pharmaceutical product with Sepracor, Inc. ("Sepracor"). Pursuant to this agreement, Andrx is using one of its controlled-release drug delivery technologies to formulate a once-a-day version of fexofenadine (previously known as terfenadine carboxylate), an antihistamine being developed by Sepracor. A twice-a-day version of this drug was approved by the FDA in 1996, and is marketed in the U.S. under the brandname Allegra/registered trademark/ by Hoechst Marion Roussel, Inc. Under thedevelopment agreement with Sepracor, the Company is responsible for developing a formulation of the product and transferring such technology to Sepracor who will be responsible for obtaining FDA approval for the product and the commercialization of the product. The Company has received certain fees under the development agreement and will be entitled to receive royalties from the sale or license of the product.